About the company
InMed Pharmaceuticals Inc, a clinical-stage biopharmaceutical company based in Canada, is at the forefront of innovative research and development in cannabinoid-based medicine. With a focus on manufacturing high-quality pharmaceutical grade cannabinoids, the company aims to address unmet medical needs and improve patient outcomes. One of InMed's promising products is INM-755, which represents a potential breakthrough in the treatment of epidermolysis bullosa (EB). EB is a rare genetic disorder that causes blistering and skin fragility due to defects in collagen production. Currently, there are limited treatment options available for this debilitating condition. INM-755, a topical cannabinoid formulation, has demonstrated significant therapeutic potential in preclinical studies. By targeting the underlying inflammation and pain associated with EB, INM-755 aspires to alleviate the symptoms and improve the quality of life for patients living with this condition. Glaucoma, a leading cause of vision loss and blindness globally, is another area where InMed is actively involved. The company's INM-088 holds promise as a potential treatment for this progressive eye disease. Glaucoma is characterized by elevated intraocular pressure, which damages the optic nerve and leads to vision loss. INM-088, an innovative cannabinoid formulation, targets the underlying factors contributing to increased eye pressure. In preclinical studies, this compound has shown to effectively reduce intraocular pressure, opening doors for a novel therapeutic approach in managing glaucoma. In addition to their novel product pipeline, InMed is also dedicated to developing advanced manufacturing technologies for Pharmaceutical-Grade Cannabinoids. The company's IntegraSyn manufacturing system is designed to optimize the production of pharmaceutical-grade cannabinoids in a cost-effective and scalable manner. This proprietary technology allows for precise control over various parameters, such as purity, potency, and consistency of the final product, ensuring a standardized formulation that meets the rigorous requirements of regulators and healthcare professionals. By providing high-quality pharmaceutical-grade cannabinoids, InMed aims to establish a strong foundation for the advancement of cannabinoid-based therapies. InMed's approach to cannabinoid-based medicine is characterized by a commitment to scientific rigor and patient-centricity. The company utilizes a proprietary bioinformatics platform, known as the IntegraSyn informatics system, to identify potential therapeutic targets and develop precise cannabinoid-based drug candidates. This cutting-edge technology allows for the efficient screening and selection of cannabinoids, maximizing the chances of identifying novel therapies with optimal therapeutic potential. Furthermore, InMed prioritizes safety and efficacy throughout the drug development process. Rigorous preclinical and clinical studies are conducted to ensure that their therapeutic candidates meet the highest standards of quality and effectiveness. The company collaborates with renowned scientific and medical experts to validate their research and gain valuable insights from leading professionals in the field. By adhering to stringent regulatory guidelines and engaging in transparent communication with regulatory agencies, InMed aims to bring their cannabinoid-based therapies to market with the utmost confidence and credibility. As the medical and scientific communities continue to explore the potential of cannabinoids in treating a wide range of diseases and conditions, InMed Pharmaceuticals Inc stands as a pioneering company committed to advancing the field. With a strong emphasis on research and development, innovative manufacturing technologies, and a patient-centric approach, InMed strives to make a meaningful impact on patients' lives and revolutionize the field of cannabinoid-based medicine.
Website: https://www.inmedpharma.com
Data updated: June 2, 2026
